The Website of the National Cancer Center (NCI) defines "cancer is a genetically related disease", which means that the occurrence of cancer is closely related to gene.So, in order to find them and put these genetic mutations in the cell and molecular level, for cancer gene mutation to design the corresponding treatments, it is very important the role of genetic testing, drug selectively destroy these mutations of tumor cells, but not destroy the normal tissue around the tumor cells,The effect of this cancer treatment is what we most want to see.
EGFR (the epidermal growth factor), a protein expressed by the EGFR gene, is involved in normal cell growth and division in healthy cells.When the EGFR gene is mutated, the EGFR protein is over expressed and assembled on the surface of the cell membrane. EGFR binds to a large number of receptors, accelerating abnormal cell growth and division, and ultimately leading to tumor progression.
At least eight mutations in the EGFR gene have been associated with lung cancer. Lung cancer is a disease in which certain cells in the lungs become abnormal and multiply uncontrollably to form a tumor. Lung cancer may not cause signs or symptoms in its early stages. Nearly all these EGFR gene mutations occur during a person's lifetime (somatic) and are present only in cancer cells.
Somatic mutations in the EGFR gene most often occur in a type of lung cancer called non-small cell lung cancer, specifically a form called adenocarcinoma. These mutations are most common in people with the disease who have never smoked. Somatic EGFR gene mutations occur more frequently in Asian populations than in white populations, occurring in 30 to 40 percent of affected Asians compared to 10 to 15 percent of whites with lung cancer.
Most of the somatic EGFR gene mutations that are associated with lung cancer delete genetic material in a part of the gene known as exon 19 or change DNA building blocks (nucleotide s) in another region called exon 21. These gene changes result in a receptor protein that is constantly turned on (consecutively activated), even when it is not bound to a ligand. As a result, cells constantly receive signals to proliferate and survive, leading to tumor formation. When these genetic changes occur in cells in the lungs, lung cancer can develop. Additional genetic, environmental, and lifestyle factors contribute to a person's cancer risk.
If exons 19-21 of the EGFR gene are accurately targeted by a Genetic Analyzer, the targeted drug can significantly increase its ability to bind to the EGFR site and kill tumor cells.Our Classic series of gene analyzers are based on Sanger sequencing principle and support 6-color and 8-color fluorescence (8-color fluorescence quantification is the state of the art) and 8/16 channels, which can be used for gene sequencing and fragment analysis to meet the needs of basic research and clinical laboratories.Tumor-targeting agents such as this EGFR gene mutation are one of the molecular diagnostic applications of our Classic gene analyzer.Using the first-generation sequencer developed and produced by Superyears, we can screen for gene mutations, detect them in time, and improve clinical detection of tumor targeting drugs to accurately target mutated genes, as well as some clinical applications: IDH1, IDH2, TERT gene/glioma typing, prognosis;H3F3A and H3F3B genes/assisted diagnosis of non-brainstem glioma and giant cell tumor of bone;Efficacy of KIT gene, PDGFRa gene/tyrosine kinase inhibitor;Prognostic assessment of disease.HER2, PIK3CA, CYP2D6, BRCA1/2 genes/prediction of disease risk, prognosis and formulation of effective treatment plan.
At present, the number of clinical terminals in China is about 10,000 units, mainly concentrated in the top three first-class hospitals and third-party medical examination institutes. In the future, the main demand comes from the equipment replacement and upgrade of the top three first-class hospitals, and the huge incremental demand of the secondary hospitals and third-party medical examination institutes. In the next five years, the domestic clinical demand gap is 20,000+ units. Sanger method has the status of the gold standard in global molecular diagnosis and is widely adopted and recognized by developed international medical systems in Europe and the United States. With the leading technical advantages of eight-color equipment and highly competitive cost performance, SUPERYEARS Gene will quickly seize the incremental clinical market worldwide and meet the huge market demand.
Classic Series gene analyzer of Nanjing Superyears Gene Technology Co., Ltd. relying on the principle of high-accuracy Sanger sequencing, open platform, compatible with mainstream reagents and consumables, the world's leading 8-color fluorescence, a maximum of 70 STR loci can be detected at one time, the efficiency of DNA database construction is improved by 100%, cost-effective products and reagents and consumables, free warranty for 1 year which are of great value in the medical field of precancerous diagnosis, genetic mutation site analysis and new drug development.
